Researchers involved in the development of the vaccine, produced using UQ’s proprietary ‘molecular clamp technology’, were disappointed, but some aspects of the work gave them encouragement.

The molecular clamp approach holds viral glycoprotein antigens in a vaccine in a precise configuration, allowing them to stimulate the immune system whilst also keeping them stable for long-term ...

London, UK-based Vicebio raised $100 million in a Series B that will help to fund the development of its Molecular Clamp technology to produce improved, more potent vaccines that are simpler to ...